Business
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patientsCOVALENT-111 (T2D) 52-week data anticipated in second half 2025COVALENT-112 (T1D) open label data anticipated in second half 2025BMF-650 IND application submission planned in second half 2025 REDWOOD
About this update from Biomea Fusion, Inc.
[{"type":"image","alt":"Biomea Fusion, Inc.","displaySize":"","headline":null,"caption":"Biomea Fusion, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/23ef33094735e204421f6d8274b615e3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gkukhuOJZCy6sOBr1Udv6Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/23ef33094735e204421f6d8274b615e3","width":300,"height":80}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Biomea preparing icovamenib for late-stage clinical development","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Multiple milestones anticipated in 2025 including:","length":50,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA meeting anticipated in first half 2025 to discuss icovamenib late-stage development in severe insulin deficient patients","length":124,"tagName":"p"}]},{"val":[{"type":"text","content":"COVALENT-111 (T2D) 52-week data anticipated in second half 2025","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"COVALENT-112 (T1D) open label data anticipated in second half 2025","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"BMF-650 IND application submission planned in second half 2025","length":62,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":492,"olType":false},{"type":"text","content":"REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, reported fourth quarter and full year 2024 financial results and corporate highlights.","length":283,"tagName":"p"},{"type":"text","content":"“2024 was a transformative year for Biomea, marked by the advancement of icovamenib into late-stage development and compelling clinical data that reinforced our confidence in its potential to reshape diabetes treatment, particularly for patients with severe insulin deficiency,” said Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member of Biomea Fusion. “As we move into this next phase, the Board made a strategic decision to align leadership wi...